JP2017505127A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505127A5
JP2017505127A5 JP2016548101A JP2016548101A JP2017505127A5 JP 2017505127 A5 JP2017505127 A5 JP 2017505127A5 JP 2016548101 A JP2016548101 A JP 2016548101A JP 2016548101 A JP2016548101 A JP 2016548101A JP 2017505127 A5 JP2017505127 A5 JP 2017505127A5
Authority
JP
Japan
Prior art keywords
segment
cell
locus
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016548101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505127A (ja
JP6479024B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/012577 external-priority patent/WO2015112790A2/en
Publication of JP2017505127A publication Critical patent/JP2017505127A/ja
Publication of JP2017505127A5 publication Critical patent/JP2017505127A5/ja
Application granted granted Critical
Publication of JP6479024B2 publication Critical patent/JP6479024B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016548101A 2014-01-24 2015-01-23 抗体親和性の最適化のための高スループットマウスモデル Active JP6479024B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931074P 2014-01-24 2014-01-24
US61/931,074 2014-01-24
PCT/US2015/012577 WO2015112790A2 (en) 2014-01-24 2015-01-23 High-throughput mouse model for optimizing antibody affinities

Publications (3)

Publication Number Publication Date
JP2017505127A JP2017505127A (ja) 2017-02-16
JP2017505127A5 true JP2017505127A5 (enExample) 2018-03-01
JP6479024B2 JP6479024B2 (ja) 2019-03-06

Family

ID=53682124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016548101A Active JP6479024B2 (ja) 2014-01-24 2015-01-23 抗体親和性の最適化のための高スループットマウスモデル

Country Status (4)

Country Link
US (2) US10034463B2 (enExample)
EP (1) EP3096609B1 (enExample)
JP (1) JP6479024B2 (enExample)
WO (1) WO2015112790A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
BR112015026197B1 (pt) 2013-04-16 2022-12-06 Regeneron Pharmaceuticals, Inc Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
EP4372090A3 (en) 2013-11-07 2024-08-07 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
KR102170502B1 (ko) 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
JP6479024B2 (ja) * 2014-01-24 2019-03-06 ザ チルドレンズ メディカル センター コーポレーション 抗体親和性の最適化のための高スループットマウスモデル
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN113444747B (zh) 2014-11-21 2025-02-11 瑞泽恩制药公司 使用成对向导rna进行靶向遗传修饰的方法和组合物
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
CN118185874A (zh) * 2016-04-04 2024-06-14 苏黎世联邦理工学院 一种重组哺乳动物b细胞
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
EP3601562A1 (en) 2017-03-23 2020-02-05 President and Fellows of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11427636B2 (en) 2017-05-01 2022-08-30 The Children's Medical Center Corporation Methods and compositions relating to anti-PD1 antibody reagents
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
JP2021500036A (ja) 2017-10-16 2021-01-07 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. アデノシン塩基編集因子の使用
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US20210238312A1 (en) * 2018-06-13 2021-08-05 The Children's Medical Center Corporation Methods and compositions relating to high-throughput models for antibody discovery and/or optimization
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
KR20210143230A (ko) 2019-03-19 2021-11-26 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
WO2022256739A2 (en) * 2021-06-04 2022-12-08 Nonagen Therapeutics Corporation Antibody specific for bcl-6 and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
CN112680475B (zh) 2008-12-18 2024-11-12 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
HUE068728T2 (hu) * 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
BR112014006394A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
LT3216871T (lt) * 2011-10-17 2022-03-25 Regeneron Pharmaceuticals, Inc. Pelės, turinčios apribotą imunoglobulino sunkiąją grandinę
KR102436654B1 (ko) 2012-06-12 2022-08-26 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
JP6479024B2 (ja) * 2014-01-24 2019-03-06 ザ チルドレンズ メディカル センター コーポレーション 抗体親和性の最適化のための高スループットマウスモデル

Similar Documents

Publication Publication Date Title
JP2017505127A5 (enExample)
JP6876853B2 (ja) 動物モデルおよび治療用分子
US11224207B2 (en) Non-human animals expressing pH-sensitive immunoglobulin sequences
CN103228130B (zh) 动物模型及治疗分子
JP6479024B2 (ja) 抗体親和性の最適化のための高スループットマウスモデル
EP2509409B1 (en) Mice that make heavy chain antibodies
DK2825036T3 (en) Histidine engineered light chain antibodies and genetically modified rodents to generate them
JP2019068857A5 (enExample)
JP2019022518A5 (enExample)
JP2020124228A (ja) ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
JP2015510769A5 (enExample)
CN111031789A (zh) 动物模型和治疗性分子
RU2016123708A (ru) Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток
EP3046412A1 (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
WO2015077072A4 (en) Non-human animals having a humanized a proliferation-inducing ligand gene
Takeuchi et al. Flp recombinase transgenic mice of C57BL/6 strain for conditional gene targeting
JP2019506897A5 (enExample)
JP2022538885A (ja) トランスジェニック哺乳動物およびその使用法
JP2021166551A (ja) 鳥類および卵
JP2021508236A5 (enExample)
JP7765403B2 (ja) ヒト化cxcl13遺伝子を有する非ヒト動物
WO2017175745A1 (ja) 生殖細胞欠損動物を用いる遺伝子改変動物の作製方法
JP2023175832A (ja) 融合タンパク質、核酸、細胞及び動物の製造方法
HK40013873A (en) Non-human animals expressing ph-sensitive immunoglobulin sequences
Cogné et al. Marie Marquet, Armand Garot, Sébastien Bender, Claire